AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The .
First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations.
AstraZeneca s Tezspire has been recommended for marketing authorisation. | July 25, 2022
Results from Phase III trials conducted by Avillion in over 4,000 patients show that PT027, a novel fixed-dose combination of albuterol and budesonide, significantly reduced the risk of a severe
/PRNewswire/ Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through.
India has approximately 30 million asthmatics, accounting for 13.09 percent of the global burden, according to the Global Burden of Disease report. Dr. Rahul Rathore, a pulmonologist at Charak Hospital, stated in a press statement on Friday that India accounts for over 42 percent of all global asthma deaths. A new study from the Global Asthma Network (GAN) revealed that the